COSMO Pharmaceuticals SA
COPN.SW
| Exchange: | SW |
| Currency | Swiss Franc |
| Open Figi: | BBG00CWWYK50 |
| ISIN: | NL0011832936 |
| LEI: | 724500OX0EBQRYTVV639 |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Drug Manufacturers - General |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Pharmaceuticals |
| Gic Sub Industry: | Pharmaceuticals |
| Description: | Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX " IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Red Hill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3S Bio, Infecto Pharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland. |
| Address: | Riverside II, Dublin, Ireland, 2 |
| Website: | https://www.cosmopharma.com |
| Full Time Employees: | 339 |
| Updated On: | 2024-11-04 |
Highlights
| Market Capitalization: | 1071866176 |
| Market Capitalization Mln: | 1071.86 |
| EBITDA: | 99911000 |
| PE Ratio: | 16.49 |
| Wall Street Target Price: | 92.03 |
| Book Value: | 31.06 |
| Dividend Share: | 2 |
| Dividend Yield: | 0.02 |
| Earnings Share: | 4.05 |
| EPS Estimate Current Year: | 7.13 |
| EPS Estimate Next Year: | 5.2 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.37 |
| Operating Margin TTM: | 0.63 |
| Return On Assets TTM: | 0.07 |
| Return On Equity TTM: | 0.14 |
| Revenue TTM: | 185356000 |
| Revenue Per Share TTM: | 11.52 |
| Quarterly Revenue Growth YOY: | 2.12 |
| Gross Profit TTM: | 32097000 |
| Diluted Eps TTM: | 4.05 |
| Quarterly Earnings Growth YOY: | 50.14 |
Valuation
| Trailing PE: | 16.49 |
| Forward PE: | 11.87 |
| Price Sales TTM: | 5.78 |
| Price Book MRQ: | 2.27 |
| Enterprise Value: | 947358398 |
| Enterprise Value Revenue: | 5.41 |
| Enterprise Value Ebitda: | 9.53 |
Shares
| Shares Outstanding: | 16045900 |
| Shares Float: | 8415586 |
| Percent Insiders: | 47.29 |
| Percent Institutions: | 12.14 |
Technicals
| Beta: | 1.25 |
| 52 Week High: | 80.6 |
| 52 Week Low: | 35.01 |
| 50 Day MA: | 75.62 |
| 200 Day MA: | 71.36 |
Splits & Dividends
| Forward Annual Dividend Rate: | 1.95 |
| Forward Annual Dividend Yield: | 0.02 |
| Dividend Date: | 2024-07-12 |
| Ex Dividend Date: | 2024-07-10 |
Earnings
| Report Date: | 2025-05-23 |
| Date: | 2025-03-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2023-03-23 |
| Date: | 2022-12-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Estimate: | 0.89 |
| Eps Difference: | -0.89 |
| Surprise Percent: | -10 |
| Report Date: | 2022-07-28 |
| Date: | 2022-06-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Estimate: | -0.06 |
| Eps Difference: | 0.06 |
| Surprise Percent: | 10 |
| Report Date: | 2022-03-23 |
| Date: | 2021-12-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | 1.47 |
| Eps Difference: | 1.47 |
| Report Date: | 2021-07-30 |
| Date: | 2021-06-30 |
| Currency: | EUR |
| Eps Actual: | -0.36 |
| Eps Estimate: | -0.4 |
| Eps Difference: | 0.04 |
| Surprise Percent: | 1 |
| Report Date: | 2021-03-26 |
| Date: | 2020-12-31 |
| Currency: | EUR |
| Eps Actual: | -0.37 |
| Eps Difference: | -0.37 |
| Report Date: | 2020-07-30 |
| Date: | 2020-06-30 |
| Currency: | EUR |
| Eps Actual: | -0.28 |
| Eps Estimate: | -0.2 |
| Eps Difference: | -0.08 |
| Surprise Percent: | -4 |
| Report Date: | 2020-04-03 |
| Date: | 2020-03-31 |
| Currency: | EUR |
| Eps Actual: | -0.28 |
| Eps Estimate: | -0.42 |
| Eps Difference: | 0.14 |
| Surprise Percent: | 33.33 |
| Report Date: | 2019-07-30 |
| Date: | 2019-06-30 |
| Currency: | EUR |
| Eps Actual: | -1.54 |
| Eps Estimate: | -1.1 |
| Eps Difference: | -0.44 |
| Surprise Percent: | -4 |
| Report Date: | 2019-03-29 |
| Date: | 2018-12-31 |
| Currency: | EUR |
| Eps Actual: | -0.76 |
| Eps Estimate: | -0.79 |
| Eps Difference: | 0.03 |
| Surprise Percent: | 3.79 |
| Report Date: | 2018-07-26 |
| Date: | 2018-06-30 |
| Currency: | EUR |
| Eps Actual: | -0.6 |
| Eps Estimate: | -1.3 |
| Eps Difference: | 0.7 |
| Surprise Percent: | 53.84 |
| Report Date: | 2018-03-26 |
| Date: | 2017-12-31 |
| Currency: | EUR |
| Eps Actual: | -1.01 |
| Eps Difference: | -1.01 |
| Report Date: | 2017-07-28 |
| Date: | 2017-06-30 |
| Currency: | EUR |
| Eps Actual: | -1.18 |
| Eps Estimate: | 0.2 |
| Eps Difference: | -1.38 |
| Surprise Percent: | -69 |
| Report Date: | 2017-03-24 |
| Date: | 2016-12-31 |
| Currency: | EUR |
| Eps Actual: | 0.78 |
| Eps Estimate: | -0.1 |
| Eps Difference: | 0.88 |
| Surprise Percent: | 88 |
| Report Date: | 2016-07-29 |
| Date: | 2016-06-30 |
| Currency: | EUR |
| Eps Actual: | 0.42 |
| Eps Estimate: | 0.1 |
| Eps Difference: | 0.32 |
| Surprise Percent: | 32 |
| Report Date: | 2016-03-23 |
| Date: | 2015-12-31 |
| Currency: | EUR |
| Eps Actual: | 0.43 |
| Eps Difference: | 0.43 |
| Report Date: | 2015-07-30 |
| Date: | 2015-06-30 |
| Currency: | EUR |
| Report Date: | 2015-03-25 |
| Date: | 2014-12-31 |
| Currency: | EUR |
| Eps Estimate: | 1.1 |
| Eps Difference: | -1.1 |
| Surprise Percent: | -10 |
| Report Date: | 2014-07-30 |
| Date: | 2014-06-30 |
| Currency: | EUR |
| Eps Actual: | 5.5 |
| Eps Estimate: | 0.1 |
| Eps Difference: | 5.4 |
| Surprise Percent: | 540 |
| Report Date: | 2014-03-27 |
| Date: | 2013-12-31 |
| Currency: | EUR |
| Eps Actual: | 0.46 |
| Eps Estimate: | 0.5 |
| Eps Difference: | -0.04 |
| Surprise Percent: | - |
| Date: | 2025-12-31 |
| Period: | +1y |
| Growth: | -0.27 |
| Earnings Estimate Avg: | 5.20 |
| Earnings Estimate Low: | 4.38 |
| Earnings Estimate High: | 5.81 |
| Earnings Estimate Year Ago Eps: | 7.13 |
| Earnings Estimate Number Of Analysts: | 4.00 |
| Earnings Estimate Growth: | -0.27 |
| Revenue Estimate Avg: | 239830000.00 |
| Revenue Estimate Low: | 227640000.00 |
| Revenue Estimate High: | 255740000.00 |
| Revenue Estimate Number Of Analysts: | 4.00 |
| Revenue Estimate Growth: | -0.06 |
| Eps Trend Current: | 5.20 |
| Eps Trend7days Ago: | 5.24 |
| Eps Trend30days Ago: | 5.13 |
| Eps Trend60days Ago: | 4.85 |
| Eps Trend90days Ago: | 4.40 |
| Date: | 2024-12-31 |
| Growth: | 100.85 |
| Earnings Estimate Avg: | 7.13 |
| Earnings Estimate Low: | 6.42 |
| Earnings Estimate High: | 7.80 |
| Earnings Estimate Year Ago Eps: | 0.07 |
| Earnings Estimate Number Of Analysts: | 4.00 |
| Earnings Estimate Growth: | 100.85 |
| Revenue Estimate Avg: | 255300000.00 |
| Revenue Estimate Low: | 248960000.00 |
| Revenue Estimate High: | 260580000.00 |
| Revenue Estimate Number Of Analysts: | 4.00 |
| Revenue Estimate Growth: | 1.72 |
| Eps Trend Current: | 7.13 |
| Eps Trend7days Ago: | 7.18 |
| Eps Trend30days Ago: | 6.94 |
| Eps Trend60days Ago: | 6.86 |
| Eps Trend90days Ago: | 6.53 |
| Eps Revisions Up Last30days: | 2.00 |
| Date: | 2024-09-30 |
| Period: | +1q |
| Date: | 2024-06-30 |
| Date: | 2024-03-31 |
| Period: | +1q |
| Date: | 2023-12-31 |
| Growth: | 3.10 |
| Earnings Estimate Avg: | 4.19 |
| Earnings Estimate Low: | 4.11 |
| Earnings Estimate High: | 4.27 |
| Earnings Estimate Year Ago Eps: | 1.02 |
| Earnings Estimate Number Of Analysts: | 2.00 |
| Earnings Estimate Growth: | 3.10 |
| Revenue Estimate Avg: | 159500000.00 |
| Revenue Estimate Low: | 110010000.00 |
| Revenue Estimate High: | 185290000.00 |
| Revenue Estimate Number Of Analysts: | 3.00 |
| Revenue Estimate Growth: | 0.60 |
| Eps Trend Current: | 4.19 |
| Eps Trend7days Ago: | 4.16 |
| Eps Trend30days Ago: | 4.12 |
| Eps Trend60days Ago: | 2.52 |
| Eps Trend90days Ago: | 1.72 |
| Date: | 2023-09-30 |
| Date: | 2023-06-30 |
| Date: | 2023-03-31 |
| Period: | +1q |
| Date: | 2022-12-31 |
| Earnings Estimate Avg: | 1.33 |
| Earnings Estimate Low: | 1.12 |
| Earnings Estimate High: | 1.53 |
| Earnings Estimate Year Ago Eps: | 1.32 |
| Earnings Estimate Number Of Analysts: | 4.00 |
| Revenue Estimate Avg: | 99860000.00 |
| Revenue Estimate Low: | 97190000.00 |
| Revenue Estimate High: | 101720000.00 |
| Revenue Estimate Number Of Analysts: | 4.00 |
| Revenue Estimate Growth: | 0.48 |
| Eps Trend Current: | 1.33 |
| Eps Trend7days Ago: | 1.31 |
| Eps Trend30days Ago: | 1.47 |
| Eps Trend60days Ago: | 1.54 |
| Eps Trend90days Ago: | 1.51 |
| Date: | 2022-09-30 |
| Date: | 2022-06-30 |
| Date: | 2019-12-31 |
| Period: | +1y |
| Growth: | 0.06 |
| Earnings Estimate Year Ago Eps: | -3.65 |
| Earnings Estimate Growth: | 0.06 |
| Revenue Estimate Avg: | 104730000.00 |
| Revenue Estimate Low: | 103310000.00 |
| Revenue Estimate High: | 106160000.00 |
| Revenue Estimate Number Of Analysts: | 2.00 |
| Revenue Estimate Growth: | 0.29 |
| Eps Trend7days Ago: | -3.17 |
| Eps Trend30days Ago: | -3.17 |
| Eps Trend60days Ago: | -3.17 |
| Eps Trend90days Ago: | -3.17 |
| Date: | 2019-06-30 |
| Period: | +1q |
| Revenue Estimate Avg: | 81200000.00 |
| Revenue Estimate Low: | 76570000.00 |
| Revenue Estimate High: | 85830000.00 |
| Revenue Estimate Number Of Analysts: | 2.00 |
| Revenue Estimate Growth: | 0.05 |
| Date: | 2019-03-31 |
| Revenue Estimate Avg: | 81200000.00 |
| Revenue Estimate Low: | 76570000.00 |
| Revenue Estimate High: | 85830000.00 |
| Revenue Estimate Number Of Analysts: | 2.00 |
| Revenue Estimate Growth: | 0.05 |
| Date: | 2018-12-31 |
| Growth: | -0.42 |
| Earnings Estimate Year Ago Eps: | -2.56 |
| Earnings Estimate Growth: | -0.42 |
| Revenue Estimate Avg: | 81200000.00 |
| Revenue Estimate Low: | 76570000.00 |
| Revenue Estimate High: | 85830000.00 |
| Revenue Estimate Number Of Analysts: | 2.00 |
| Revenue Estimate Growth: | 0.05 |
| Eps Trend7days Ago: | -1.46 |
| Eps Trend30days Ago: | -1.46 |
| Eps Trend60days Ago: | -1.46 |
| Eps Trend90days Ago: | -1.46 |
| Date: | 2018-09-30 |
| Period: | +1q |
| Date: | 2018-06-30 |
| Date: | 2022-12-31 |
| Date: | 2021-12-31 |
| Eps Actual: | 1.1 |
| Date: | 2020-12-31 |
| Eps Actual: | -2.4 |
| Date: | 2018-12-31 |
| Eps Actual: | -1.3 |
| Date: | 2017-12-31 |
| Eps Actual: | -2.1 |
| Date: | 2016-12-31 |
| Eps Actual: | 1. |
| Date: | 2015-12-31 |
| Eps Actual: | 0.4 |
| Date: | 2014-12-31 |
| Eps Actual: | 5. |
| Date: | 2013-12-31 |
| Eps Actual: | 0.4 |